The Living Guidelines: STEMI Recommendations for Inhibition of the Renin-Angiotensin-Aldosterone System Polling Results for CLASS IIa Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class IIa
1. In STEMI patients who tolerate ACE inhibitors, an ARB can be useful as an alternative to ACE inhibitors in the long-term management of STEMI patients, provided there are either clinical or radiological signs of heart failure or LVEF less than 0.40. Valsartan and candesartan have established efficacy for this recommendation. (Level of Evidence: B)

 AHA / ACC 2007 STEMI Guidelines Inhibition of the Renin-Angiotensin-Aldosterone System Class IIa Recommendation 1 should be: CLASS I CLASS IIa CLASS IIb CLASS III